ArticleCancer discovery2020
EGFR Blockade Reverts Resistance to KRAS
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 316 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
316citing papers in PubMed, 4 pooled it
20.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
316 citing papers in PubMed, 4 syntheses or guidelines pooled it, 453 citations in OpenAlex.
- Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.The oncologist · 2026Pooled it
- KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.Journal of translational medicine · 2025Pooled it
- Research trends and hotspots of circulating tumor DNA in colorectal cancer: a bibliometric study.Frontiers in oncology · 2025Pooled it
- Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.The oncologist · 2023Pooled it
- D3S-001 in advanced solid tumors with KRASNature medicine · 2025Trial
- Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Signal transduction and targeted therapy · 2025Trial
- Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.Nature communications · 2025Trial
- Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Cancer discovery · 2024Trial
- Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma.Experimental hematology & oncology · 2026Article
- Review
- Mutant KRAS-mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASNature medicine · 2026Article
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer · 2026Review
- KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target.Current oncology (Toronto, Ont.) · 2026Review
- KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Journal of gastrointestinal cancer · 2026Review
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Targeting β-Adrenergic Signaling in Colorectal Cancer: Molecular Mechanisms and Therapeutic Potential of β-Blockers.Cancers · 2026Review
- PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Cancer research · 2026Article
- Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms.Translational oncology · 2026Article
256 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
29 authors at 6 institutions in 3 countries.
Vito Amodio *Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Rona Yaeger *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Pamela Arcella *Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Carlotta CancelliereCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Simona LambaCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Annalisa LorenzatoCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Sabrina ArenaCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.ORCID https://orcid.org/0000-0002-1318-2494
Monica MontoneCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.ORCID https://orcid.org/0000-0001-7907-4333
Benedetta MussolinCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.ORCID https://orcid.org/0000-0001-5723-5685
Yu BianMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Adele WhaleyMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Marika PinnelliCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Yonina R Murciano-GoroffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Efsevia VakianiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nicola ValeriCenter for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Wei-Li LiaomProbe Inc., Rockville, Maryland.
Anuja BhalkikarmProbe Inc., Rockville, Maryland.
Sheeno ThyparambilmProbe Inc., Rockville, Maryland.
Hui-Yong ZhaoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Silvia MarsoniNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Salvatore SienaNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.ORCID https://orcid.org/0000-0002-2681-2846
Andrea BertottiCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Livio TrusolinoCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Bob T LiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-6661-8733
Neal RosenMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Federica Di NicolantonioCandiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.ORCID https://orcid.org/0000-0001-9618-2010
Alberto Bardelli *Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy. misales@mskcc.org alberto.bardelli@unito.it.
Sandra Misale *Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. misales@mskcc.org alberto.bardelli@unito.it.
Candiolo Cancer Institute · ITMemorial Sloan Kettering Cancer Center · USPredictionProbe (United States) · USAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITInstitute of Cancer Research · GBUniversity of Milan · IT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2007 to 2026
$31.2MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MExploiting the distinct genomics and signaling of colorectal cancers to effectively target ERKR01CA233736 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI YAEGER, RONA · 2019 to 2024
$2.5MCancer Research UK 18052European Research Council 724748NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA233736NCI NIH HHS R35 CA210085NIH HHS U54 OD020355
Abstract
Most patients with
Indexed as
AnimalsAntineoplastic AgentsCell Line, TumorCetuximabColorectal NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansMice, SCIDPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridinesPyrimidinesAntineoplastic AgentsCetuximabEGFR protein, humanErbB ReceptorsKRAS protein, humanPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.